Robert C. Goeltz II
2019 - Unity Biotechnology
In 2019, Robert C. Goeltz II earned a total compensation of $1.6M as Chief Financial Officer at Unity Biotechnology, a 79% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $166,100 |
|---|---|
| Option Awards | $853,916 |
| Salary | $400,000 |
| Stock Awards | $189,675 |
| Other | $11,200 |
| Total | $1,620,891 |
Goeltz received $853.9K in option awards, accounting for 53% of the total pay in 2019.
Goeltz also received $166.1K in non-equity incentive plan, $400K in salary, $189.7K in stock awards and $11.2K in other compensation.
Rankings
In 2019, Robert C. Goeltz II's compensation ranked 6,940th out of 13,971 executives tracked by ExecPay. In other words, Goeltz earned more than 50.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,940 out of 13,971 | 50th |
Division Manufacturing | 2,653 out of 5,695 | 53rd |
Major group Chemicals And Allied Products | 967 out of 2,194 | 56th |
Industry group Drugs | 817 out of 1,880 | 57th |
Industry Pharmaceutical Preparations | 599 out of 1,392 | 57th |
Source: SEC filing on April 24, 2020.
Goeltz's colleagues
We found three more compensation records of executives who worked with Robert C. Goeltz II at Unity Biotechnology in 2019.